Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03774264 · ClinicalTrials.gov registry record

Treatment Response to Xiaflex for Men With Peyronie's Disease

A clinical trial of Peyronie Disease, sponsored by University of Miami.

Completed
Registry status
80
Enrollment target
1
Study location

NCT03774264: Completed study of Peyronie Disease, sponsored by University of Miami.

NCT03774264 is a study of Peyronie Disease that has completed, run by University of Miami. The registered enrollment target is 80 participants, above the 41-participant average among 3 other Peyronie Disease trials with a reported enrollment target (95% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03774264, a study of Peyronie Disease, has completed, sponsored by University of Miami.

COMPLETED
Registry status
80 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to develop a database of patients with Peyronie's disease who are treated at the University of Miami. The collected data will help the researchers to better understand Peyronie's disease and its response to therapy.

Primary Outcome

The PDQ is highly responsive to treatment-related change in men with PD. It is self-administered, that measures psychosexual consequences after the presentation of PD. It is intended for men who have had vaginal intercourse in the past 3 months. The range of scores is from 0-24 points, with higher scores signifying greater psychosexual consequences from PD.

Conditions Studied

Study Locations (1)

Florida

  • Department of Urology, University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2018-09-02
Est. Completion 2021-07-02
University of Miami

721 total trials

What the finished NCT03774264 record still lists

NCT03774264 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 41-participant average among 3 other Peyronie Disease trials with a reported enrollment target (95% higher).

The record links to 1 condition, with Peyronie Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03774264 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03774264 about?

NCT03774264 is a clinical study titled "Treatment Response to Xiaflex for Men With Peyronie's Disease". The purpose of this research study is to develop a database of patients with Peyronie's disease who are treated at the University of Miami. The collected data will help the researchers to better understand Peyronie's disease and its response to therapy.

What is the current status of trial NCT03774264?

This trial is currently completed. The enrollment target is 80 participants. The study started on 2018-09-02. Estimated completion is 2021-07-02.

What conditions does trial NCT03774264 study?

This clinical trial studies the following conditions: Peyronie Disease.

Who is sponsoring clinical trial NCT03774264?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03774264 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peyronie Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03774264, the US trial registry maintained by the National Library of Medicine. NCT03774264 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.